OS Therapies Inc Chief Commercial Officer Kerry M. Clem filed a Form 4 on October 30, 2026, disclosing the grant of stock options to purchase 300,000 shares of common stock on October 22, 2026.

Key Highlights

  • Reporting person: Kerry M. Clem, Chief Commercial Officer of OS Therapies Inc (NASDAQ:OSTX)
  • Option grant date: October 22, 2026
  • Shares underlying options: 300,000 shares of common stock
  • Exercise price: $1.25 per share
  • Expiration date: October 22, 2036
  • Vesting schedule: 12 equal monthly installments beginning on each monthly anniversary of the grant date, subject to continued employment
  • Plan: Granted under the issuer's amended and restated 2023 incentive compensation plan

OS Therapies Chief Commercial Officer Receives October 2026 Stock Option Award

According to the Form 4 filing, Kerry M. Clem, serving as Chief Commercial Officer of OS Therapies Inc, received a grant of stock options (right to buy) on October 22, 2026, covering 300,000 shares of the company's common stock. The filing identifies the transaction code as "A," indicating an acquisition of derivative securities. The exercise price is listed as $1.25 per share, and the options carry an expiration date of October 22, 2036, giving them a ten-year term.

The filing's explanation of responses states: "On October 22, 2026, the reporting person was granted options to purchase 300,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement and the issuer's amended and restated 2023 incentive compensation plan." The price of the derivative security at grant is listed as $0. Following the reported transaction, Clem beneficially owns 300,000 of these stock options directly.

The options vest in 12 equal installments on each monthly anniversary of the grant date, according to the filing, "provided that the reporting person is serving as an employee of the issuer on each applicable vesting date." The filing also discloses that Table I reflects 25,000 shares of common stock beneficially owned directly, though no transaction date, transaction code, or price is recorded in that row. The Form 4 was filed by one reporting person and signed by Kerry M. Clem on October 30, 2026.

What Was Disclosed

Kerry M. Clem, Chief Commercial Officer of OS Therapies Inc, disclosed the grant of options to purchase 300,000 shares of common stock at $1.25 per share on October 22, 2026, vesting monthly over 12 installments, under the company's amended and restated 2023 incentive compensation plan.